Latest News and Press Releases

-- New first-in-class compounds LAF237 (diabetes) and SPP100 (hypertension) set for submission in 2006 -- Robust pipeline with 75 compounds in development, including 52 in Phase II/III...

HOLZKIRCHEN, Germany, Sept. 13, 2005 (PRIMEZONE) -- Sandoz announced today that it has filed a lawsuit against the U.S. Food and Drug Administration seeking a ruling on its pending new drug...

BASEL, Switzerland and CAMBRIDGE, Mass., Sept. 7, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS), and Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced today a major multi-year alliance focused on the...

BASEL, Switzerland, Sept. 1, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has made a proposal to the independent directors of Chiron Corporation (Nasdaq:CHIR) to acquire all of the...

BASEL, Switzerland, Aug. 31, 2005 (PRIMEZONE) -- A head-to-head study published in The New England Journal of Medicine (NEJM)(1) showed that a single dose of Aclasta(a) (zoledronic acid 5mg solution...

BASEL, Switzerland, Aug. 29, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that the US Food and Drug Administration has granted priority review to Femara(R) (letrozole) in the adjuvant...

BASEL, Switzerland, Aug. 18, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has signed an agreement with SeBo GmbH of Germany to acquire the global rights for a novel oral phosphate...

BASEL, Switzerland, July 28, 2005 (PRIMEZONE) -- -- Novartis and Idenix anticipate first regulatory filings by the end of 2005 -- Complete GLOBE results to be submitted for presentation at...

BASEL, Switzerland, July 28, 2005 (PRIMEZONE) -- Novartis AG (NYSE:NVS): - Schering AG and Novartis AG to disclose findings of independent Data Safety Monitoring Board on CONFIRM 2 - PTK/ZK's...

BASEL, Switzerland, July 27, 2005 (PRIMEZONE) -- Novartis announced today the final results of the cash tender offer by Zodnas Acquisition Corp., an indirect wholly owned subsidiary of Novartis AG,...